Bandyopadhyay Ananda S, Garon Julie, Seib Katherine, Orenstein Walter A
2Division of Infectious Diseases, Emory University School of Medicine, 1462 Clifton Road, Room 446, Atlanta, GA 30322, USA.
Future Microbiol. 2015;10(5):791-808. doi: 10.2217/fmb.15.19. Epub 2015 Mar 31.
Live attenuated oral polio vaccine (OPV) and inactivated polio vaccine (IPV) are the tools being used to achieve eradication of wild polio virus. Because OPV can rarely cause paralysis and generate revertant polio strains, IPV will have to replace OPV after eradication of wild polio virus is certified to sustain eradication of all polioviruses. However, uncertainties remain related to IPV's ability to induce intestinal immunity in populations where fecal-oral transmission is predominant. Although substantial effectiveness and safety data exist on the use and delivery of OPV and IPV, several new research initiatives are currently underway to fill specific knowledge gaps to inform future vaccination policies that would assure polio is eradicated and eradication is maintained.
口服脊髓灰质炎减毒活疫苗(OPV)和脊髓灰质炎灭活疫苗(IPV)是用于实现根除野生脊髓灰质炎病毒的工具。由于OPV极少会导致瘫痪并产生脊髓灰质炎回复毒株,在野生脊髓灰质炎病毒根除得到认证后,IPV将必须取代OPV以维持所有脊髓灰质炎病毒的根除。然而,对于IPV在粪口传播占主导的人群中诱导肠道免疫的能力仍存在不确定性。尽管关于OPV和IPV的使用及接种已有大量有效性和安全性数据,但目前正在开展若干新的研究项目以填补特定知识空白,为未来的疫苗接种政策提供依据,确保脊髓灰质炎被根除并持续保持无脊髓灰质炎状态。